Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Effectiveness of Trastuzumab As Adjuvant Therapy in Patients With Early Stage Breast Cancer: A Systematic Review and Meta-Analysis Publisher



Davari M1, 2 ; Amani B3 ; Mokarian F4 ; Hoseini M5 ; Akbarzadeh A6 ; Khoramabadi NH7
Authors
Show Affiliations
Authors Affiliations
  1. 1. Department of Pharmacoeconomics and Pharmaceutical Administration, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran
  2. 2. Pharmaceutical Management and Economics Research Center, Tehran University of Medical Sciences, Tehran, Iran
  3. 3. Department of Health Management and Economics, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran
  4. 4. Breast cancer Research center, Isfahan University of Medical Science, Isfahan, Iran
  5. 5. Department of Biostatistics and Epidemiology, School of Health, Isfahan University of Medical Sciences, Isfahan, Iran
  6. 6. Department of Epidemiology and Biostatistics, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran
  7. 7. Department of Drug and Food Control, School of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran

Source: Medical Journal of the Islamic Republic of Iran Published:2017


Abstract

Background: Trastuzumab in combination with chemotherapy has long been established as a standard treatment for HER2-positive patients in early stage breast cancer (BC). The present study aimed at assessing the effectiveness of trastuzumab adjuvant therapy in early stage BC in overall survival (OS) and disease-free survival (DFS). Methods: A systematic review and meta-analysis was performed to evaluate the effectiveness of trastuzumab adjuvant therapy. Pub- Med, Cochrane library, Scopus, Web of Science, and Embase databases were searched for relevant RCTs from the beginning to February 2017. Quality assessment of studies was conducted using the Cochrane Risk of Bias Tool. The desired outcomes were OS and DFS. Results: A total of 1818 articles were identified first, however, only 11 studies were eligible to be included in this study. Our findings and meta-analysis results revealed that trastuzumab is effective in increasing OS (OS hazard ratio: -0.286 ± 0.049, 95%CI (-0.381, - 0.191)) and improving DFS (DFS hazard ratio: -0.419± 0.077, 95%CI (-0.569, -0.269)). The most serious but negligible side effect of trastuzumab is congestive heart failure. Conclusion: Adding trastuzumab as adjuvant therapy in early stages of BC in HER2 positive patients could increase OS and DFS of the patients effectively. © Iran University of Medical Sciences.
Related Docs
1. A Randomized, Double-Blind, Phase Iii, Non-Inferiority Clinical Trial Comparing the Efficacy and Safety of Ta4415v (A Proposed Trastuzumab Biosimilar) and Herceptin (Trastuzumab Reference Product) in Her2-Positive Early-Stage Breast Cancer Patients, BMC Pharmacology and Toxicology (2022)
2. Development and Biological Assessment of Mmae-Trastuzumab Antibody–Drug Conjugates (Adcs), Breast Cancer (2021)
3. The Role of Her2 Alterations in Clinicopathological and Molecular Characteristics of Breast Cancer and Her2-Targeted Therapies: A Comprehensive Review, Medical Oncology (2022)
4. Breast Cancer in the Era of Precision Medicine, Molecular Biology Reports (2022)
5. New Insights Into Affinity Proteins for Her2-Targeted Therapy: Beyond Trastuzumab, Biochimica et Biophysica Acta - Reviews on Cancer (2020)
6. Trastuzumab-Induced Cardiomyopathy Evaluation by Combined Echocardiography and Biomarkers in Patients With Breast Cancer, Iranian Heart Journal (2015)
7. A Randomized, Double-Blind, Parallel Pharmacokinetic Study Comparing the Trastuzumab Biosimilar Candidate, Aryotrust®, and Reference Trastuzumab in Healthy Subjects, Expert Opinion on Investigational Drugs (2020)
8. Comparing Efficacy and Safety of P013, a Proposed Pertuzumab Biosimilar, With the Reference Product in Her2-Positive Breast Cancer Patients: A Randomized, Phase Iii, Equivalency Clinical Trial, BMC Cancer (2022)
Experts (# of related papers)
View all Related Experts
Farhad Shahi (3)
Mehrzad Mirzania (2)